Systemic safety of anti-VEGF drugs: a commentary

@article{Scott2015SystemicSO,
  title={Systemic safety of anti-VEGF drugs: a commentary},
  author={Lauren J. Scott and Usha Chakravarthy and Barnaby C. Reeves and Chris A. Rogers},
  journal={Expert Opinion on Drug Safety},
  year={2015},
  volume={14},
  pages={379 - 388}
}
Introduction: VEGF is a mediator of angiogenesis. Thus, concerns have been expressed following the use of VEGF inhibitors for the treatment of neovascular age-related macular degeneration (nAMD). Ranibizumab, and more recently aflibercept, are VEGF inhibitors licensed for the treatment of nAMD. Bevacizumab is also used but unlicensed for this application. Areas covered: A non-systematic review of nAMD trials was undertaken to investigate four outcomes: all-cause mortality, all systemic serious… Expand
Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues
TLDR
The proteins established in nAMD therapy show similar efficacies, and anti-VEGF therapy is well tolerated, and low rates of ocular and systemic AEs in smaller trials suggest a very high benefit/risk ratio. Expand
Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy
TLDR
The data support the notion that clinically nonbeneficial treatments with anti-VEGF drugs could potentially cause adverse effects and show that the fenestrated microvasculature in endocrine organs are more sensitive than tumor vasculatures in response to systemic anti-veGF drugs. Expand
Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies
TLDR
Published data on IVTB in AMRD provide only a low level of evidence on its cardiovascular safety and do not support any finite conclusions. Expand
Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
TLDR
The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF, and the rates of SAEs in both groups were low. Expand
Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model
TLDR
The effectiveness of EMP2 as a novel target in pathologic corneal neovascularization in an animal model is demonstrated and supports additional investigation into EMP2 antibody blockade as a potential new therapeutic option. Expand
Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser.
TLDR
Although favourable and promising outcomes were obtained with intravitreal injection of anti-vascular endothelial growth factor agents for the treatment of ROP, concerns have been raised about potential systemic side effects, including potential cardiovascular side effects caused by these agents. Expand
Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
TLDR
Rates of selected ocular and systemic adverse events with IAI were similar to those of controls and similar across disease states in evaluated IAI trials, and generally well tolerated in the patients evaluated. Expand
Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial.
TLDR
Subretinal delivery of rAAV.sFLT-1 was well tolerated and demonstrated a favourable safety profile through month 36, and could be safely considered for future evaluation in the treatment of wet AMD. Expand
A Pilot Clinical Study of Intravitreal Injection of Artesunate for Ocular Neovascularization.
  • Cheng Li, Xiaoxiao Feng, +14 authors Q. Gao
  • Medicine
  • Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2019
TLDR
This pilot study determined that intravitreal artesunate injection is efficacious for reducing corneal, iris, and retinal neovascularization and indicates that this drug may be a novel alternative to the currently popular antivascular endothelial growth factor drugs used to suppress ocular neov vascularization and improve visual function. Expand
Intravitreal anti‐VEGF therapy is not associated with a higher risk of all‐cause mortality in patients with macular oedema caused by posterior segment vascular diseases
TLDR
Intravitreal anti-VEGF therapy was not associated with an increase in the risk of mortality in patients with MO compared with age- and sex-matched controls and Cox´s proportional hazards model showed no difference. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review
TLDR
A review of clinical research studies in wAMD published since 2008 that compared anti-VEGF dosing regimens and therapies found treatment outcomes were generally better for both drugs when more aggressive retreatment criteria were used, which resulted in more frequent injections. Expand
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
TLDR
The findings in the Inhibition of VEGF in Age-related choroidal Neovascularisation trial highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought. Expand
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
TLDR
Evidence from head-to-head trials raises concern about an increased risk of ocular and multiple systemic AE with bevacizumab, and clinicians and patients should continue to carefully weight up the benefits and harms when choosing between the two treatment options. Expand
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
TLDR
The comparison of visual acuity at 1 year between bevacizumab and ranibizumabs was inconclusive, and other outcomes are consistent with the drugs and treatment regimens having similar efficacy and safety. Expand
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
TLDR
In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Expand
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
TLDR
Intravitreal ranibizumab was safe and well tolerated in a large population of subjects with neovascular AMD and had a beneficial effect on VA, and future investigations will seek to establish optimal dosing regimens for persons with nevascular AMD. Expand
MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS: A Whole Population Study
TLDR
Patients treated with vascular endothelial growth factor inhibitors were significantly more likely to experience fatal or nonfatal MI than the community group, and this increased risk may be related to the underlying age-related macular degeneration or vascular endothelium growth factor inhibitor use itself. Expand
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
TLDR
Bvacizumab was noninferior to ranibizumAB for visual acuity at 1 year with similar safety profiles, and Ranibizuab tended to have a better anatomic outcome. Expand
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
TLDR
Bvaczumab and ranibizumab had equivalent effects on visual acuity at 1 year when administered according to a treat-and-extend protocol, and the visual acute results were comparable to those of other clinical trials with monthly treatment. Expand
Ranibizumab for neovascular age-related macular degeneration.
TLDR
Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. Expand
...
1
2
3
4
...